MEDINCELL S.A. |
Market Closed -
Other stock markets
|
After market 01:59:18 pm | |||
| 16.22 EUR | -0.49% |
|
16.19 | -0.18% |
| Dec. 13 | Eutelsat: delisted from the SBF 120 and CAC Mid 60 indices | CF |
| Dec. 13 | Euroapi: delisted from the SBF 120 and CAC Mid 60 indices | CF |
Projected Income Statement: MedinCell S.A.
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.852 | 8.186 | 4.091 | 9.889 | 9.032 | 22.21 | 39.34 | 83.2 |
| Change | - | 187.03% | -50.02% | 141.73% | -8.67% | 145.87% | 77.15% | 111.49% |
| EBITDA 1 | - | - | -22.3 | -22.36 | -19.26 | -10.4 | 7 | 44.2 |
| Change | - | - | - | 0.29% | -13.87% | 46% | - | 531.43% |
| EBIT 1 | -19.32 | -15.37 | -23.81 | -24.02 | -20.94 | -7.406 | 14.98 | 46.4 |
| Change | - | -20.47% | 54.95% | 0.89% | -12.84% | 64.63% | - | 209.75% |
| Interest Paid 1 | - | - | -1.754 | -7.964 | -3.973 | -6 | -4 | -4 |
| Earnings before Tax (EBT) 1 | - | - | -24.81 | -32.01 | -24.95 | -24.54 | -7.2 | - |
| Change | - | - | - | 29.04% | -22.06% | 1.65% | 70.66% | 100% |
| Net income 1 | -23.92 | -19.02 | -24.81 | -29.5 | -25.04 | -15.59 | 10.1 | 38.5 |
| Change | - | -20.47% | 30.42% | 18.91% | -15.12% | 37.74% | - | 281.19% |
| Announcement Date | 6/4/20 | 6/16/21 | 6/14/22 | 6/26/23 | 6/10/24 | - | - | - |
1EUR in Million
Estimates
Forecast Balance Sheet: MedinCell S.A.
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 22.9 | 48.2 | 42.3 | 47.3 | 35.8 | 14.5 |
| Change | - | - | - | 110.48% | -12.24% | 11.7% | -24.31% | -59.5% |
| Announcement Date | 6/4/20 | 6/16/21 | 6/14/22 | 6/26/23 | 6/10/24 | - | - | - |
1EUR in Million
Estimates
Cash Flow Forecast: MedinCell S.A.
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 1.974 | 1.027 | 1.191 | 1.3 | 1.775 | 0.95 |
| Change | - | -47.97% | 15.97% | 9.15% | 36.54% | -46.48% |
| Free Cash Flow (FCF) 1 | -22.98 | -22.03 | -13.11 | -3.25 | 5.167 | 32.2 |
| Change | - | -4.15% | -40.48% | -75.22% | -258.97% | 523.23% |
| Announcement Date | 6/14/22 | 6/26/23 | 6/10/24 | - | - | - |
1EUR in Million
Estimates
Forecast Financial Ratios: MedinCell S.A.
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | -545% | -226.11% | -213.22% | -46.83% | 17.79% | 53.12% |
| EBIT Margin (%) | -677.56% | -187.74% | -582.06% | -242.95% | -231.84% | -33.35% | 38.08% | 55.77% |
| EBT Margin (%) | - | - | -606.36% | -323.69% | -276.24% | -110.5% | -18.3% | - |
| Net margin (%) | -838.53% | -232.35% | -606.36% | -298.29% | -277.21% | -70.2% | 25.67% | 46.27% |
| FCF margin (%) | - | - | -561.84% | -222.79% | -145.18% | -14.64% | 13.13% | 38.7% |
| FCF / Net Income (%) | - | - | 92.66% | 74.69% | 52.37% | 20.85% | 51.16% | 83.64% |
Profitability | ||||||||
| ROA | - | - | - | - | - | - | - | 476.1% |
| ROE | - | - | - | - | - | - | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | -1.03x | -2.15x | -2.2x | -4.55x | 5.11x | 0.33x |
| Debt / Free cash flow | - | - | -1x | -2.19x | -3.23x | -14.55x | 6.92x | 0.45x |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | 48.25% | 10.39% | 13.19% | 5.85% | 4.51% | 1.14% |
| CAPEX / EBITDA (%) | - | - | -8.85% | -4.59% | -6.18% | -12.5% | 25.36% | 2.15% |
| CAPEX / FCF (%) | - | - | -8.59% | -4.66% | -9.08% | -40% | 34.35% | 2.95% |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | -0.83 | -0.4195 | -0.8 | -0.2 | 0.8 |
| Change | - | - | - | - | -49.46% | 90.7% | -75% | -500% |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | -0.5325 | -1.673 | -1.436 | -1.7 | 0.05 | - |
| Change | - | - | - | 214.18% | -14.14% | 18.34% | -102.94% | - |
| EPS 1 | -1.19 | -0.86 | -1 | -1.27 | -0.88 | -0.6333 | 0.4233 | 1.32 |
| Change | - | -27.73% | 16.28% | 27% | -30.71% | -28.03% | -166.84% | 211.81% |
| Nbr of stocks (in thousands) | 20,097 | 24,581 | 25,121 | 25,101 | 28,749 | 29,229 | 29,229 | 29,229 |
| Announcement Date | 6/4/20 | 6/16/21 | 6/14/22 | 6/26/23 | 6/10/24 | - | - | - |
1EUR
Estimates
| 2025 * | 2026 * | |
|---|---|---|
| P/E ratio | -25.7x | 38.5x |
| PBR | -9.59x | 326x |
| EV / Sales | 23.6x | 13x |
| Yield | - | - |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.30EUR
Average target price
22.83EUR
Spread / Average Target
+40.08%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MEDCL Stock
- Financials MedinCell S.A.